» Articles » PMID: 31505837

The Phenylethanol Glycoside Liposome Inhibits PDGF-Induced HSC Activation Via Regulation of the FAK/PI3K/Akt Signaling Pathway

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2019 Sep 12
PMID 31505837
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

is a traditional Chinese herbal medicine that is widely used to regulate immunity, and phenylethanol glycosides (CPhGs) are among the primary components responsible for this activity. However, the application of CPhGs is negatively affected by their poor absorption and low oral utilization. Targeted drug delivery is an important development direction for pharmaceutics. Previous studies have indicated that CPhGs could block the conduction of the signaling pathways in TGF-β1/smad and inhibit the activation of hepatic stellate cells (HSCs). The aim of this study was to evaluate the anti-hepatic fibrosis effect of CPhG liposomes by inhibiting HSC activation, promoting apoptosis, blocking the cell cycle, suppressing the conduction of signaling pathways in focal adhesion kinase(FAK)/phosphatidylinositol-3-kinase(PI3K)/protein kinase B(Akt), and determining their in vitro hepatoprotective activity. In vitro release studies demonstrated that CPhG liposomes have a sustained release effect compared to drug CPhGs. HSC proliferation was inhibited after treatment with the CPhG liposomes (29.45, 14.72, 7.36 µg/mL), with IC values of 42.54 µg/mL in the MTT assay. Different concentrations of the CPhG liposomes could inhibit HSC proliferation, promote apoptosis, and block the cell cycle. The MTT method showed an obvious inhibition of HSC proliferation after CPhG liposome and Recombinant Rat Platelet-derived growth factor-BB(rrPDGF-BB) treatment. The levels of collagen-1, metallopeptidase inhibitor 1 (TIMP-1), α smooth muscle actin (α-SMA), and phosphorylated PI3K/Akt were downregulated, and matrix metalloproteinase-1 (MMP-1) was upregulated, by pretreatment with different concentrations of CPhG liposomes. Moreover, 29.45 μg/mL of CPhG liposomes could decrease the expression of the FAK protein and the phosphorylated PI3K and Akt protein downstream of FAK by overexpression of the FAK gene. This experiment suggests that CPhG liposomes may inhibit the activation of HSCs by inhibiting FAK and then reducing the expression of phosphorylated Akt/PI3K, thereby providing new insights into the application of CPhGs for liver fibrosis.

Citing Articles

Phenylethanol Glycoside from Attenuates BSA-Induced Liver Fibrosis in Rats by Modulating the Gut Microbiota-Liver Axis.

Qi X, Sun H, Liu J, Cong M, Zhang X, Yan Y Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338312 PMC: 11435394. DOI: 10.3390/ph17091149.


Quantitative proteomics reveals the protective effects of Yinchenzhufu decoction against cholestatic liver fibrosis in mice by inhibiting the PDGFRβ/PI3K/AKT pathway.

Meng Q, Zhu H, Li Y, Peng X, Wang T, Huang H Front Pharmacol. 2024; 15:1341020.

PMID: 38469403 PMC: 10926276. DOI: 10.3389/fphar.2024.1341020.


RUNX1 promotes liver fibrosis progression through regulating TGF-β signalling.

Guo Z, Liu X, Zhao S, Sun F, Ren W, Ma M Int J Exp Pathol. 2023; 104(4):188-198.

PMID: 37070207 PMC: 10349244. DOI: 10.1111/iep.12474.


Galangin delivered by retinoic acid-modified nanoparticles targeted hepatic stellate cells for the treatment of hepatic fibrosis.

Xiong Y, Wu B, Guo X, Shi D, Xia H, Xu H RSC Adv. 2023; 13(16):10987-11001.

PMID: 37033441 PMC: 10077338. DOI: 10.1039/d2ra07561j.


CaM/CaMKII mediates activation and proliferation of hepatic stellate cells regulated by ASIC1a.

Liu H, Lu W, Hong H, Li M, Ye M, Rao Q Front Pharmacol. 2023; 13:996667.

PMID: 36588718 PMC: 9797583. DOI: 10.3389/fphar.2022.996667.


References
1.
Zhang H, Sun D, Wang G, Cui S, Field R, Li J . Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell. Biochem Biophys Res Commun. 2019; 511(2):387-393. DOI: 10.1016/j.bbrc.2019.02.065. View

2.
Sakai-Kato K, Yoshida K, Izutsu K . Effect of surface charge on the size-dependent cellular internalization of liposomes. Chem Phys Lipids. 2019; 224:104726. DOI: 10.1016/j.chemphyslip.2019.01.004. View

3.
Ezhilarasan D, Sokal E, Najimi M . Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets. Hepatobiliary Pancreat Dis Int. 2018; 17(3):192-197. DOI: 10.1016/j.hbpd.2018.04.003. View

4.
Li Y, Lu A, Long M, Cui L, Chen Z, Zhu L . Nitroimidazole derivative incorporated liposomes for hypoxia-triggered drug delivery and enhanced therapeutic efficacy in patient-derived tumor xenografts. Acta Biomater. 2018; 83:334-348. DOI: 10.1016/j.actbio.2018.10.029. View

5.
Li M, Li Y, Liu W, Li R, Qin C, Liu N . The preparation of Cistanche phenylethanoid glycosides liquid proliposomes: Optimized formulation, characterization and proliposome dripping pills in vitro and in vivo evaluation. Eur J Pharm Sci. 2016; 93:224-32. DOI: 10.1016/j.ejps.2016.07.020. View